News Opinion Editor's Corner ESC 2022 What’s Going to Be Hot at ESC 2022? Shelley Wood August 22, 2022
News Opinion Editor's Corner TCTMD’s Top 10 Most Popular Stories for January 2022 Shelley Wood January 31, 2022
News Daily News Rivaroxaban Again Linked to More Bleeding vs Other DOACs Caitlin E. Cox October 11, 2021
News Daily News Observational Study Supports Continuing Oral Anticoagulation During PCI Michael O'Riordan April 06, 2021
News Daily News Rivaroxaban-Aspirin Combo Works in ASCVD Across BMI Groups Todd Neale February 01, 2021
News Conference News ESC 2020 VOYAGER PAD: CAD Subanalysis Finds Fewer CV, Limb Events With Rivaroxaban L.A. McKeown September 03, 2020
News Daily News New Guidance on Use of Diabetes Drugs for CVD Risk Reduction: ACC Experts Michael O'Riordan August 06, 2020
News Conference News ACC 2020 Diabetes May Boost Benefits of COMPASS Dual Antithrombotic Approach Todd Neale March 28, 2020
News Daily News COMPASS Antithrombotic Approach Works Well in Prior-PCI Patients Todd Neale March 27, 2020
News Opinion Editor's Corner A ‘Virtual’ ACC 2020? TCTMD Has You Covered, However Things Roll Out Shelley Wood March 16, 2020
News Daily News New Meta-analysis Supports NOAC Plus P2Y12 Inhibitor for PCI in A-fib Shelley Wood February 28, 2020
Presentation JIM 2020 Long term antithrombotic therapy in high risk PCI: Consider low-dose rivaroxaban with SAPT Presenter: Giuseppe Tarantini February 13, 2020
News Daily News Most Secondary Prevention Patients Are Eligible for Multiple Drugs Michael O'Riordan January 03, 2020
News Daily News Switch Anticoagulants for A-fib Patients Needing a Stent? RE-DUAL PCI Insights Shelley Wood December 02, 2019
News Conference News AHA 2019 AHA 2019: Beyond ISCHEMIA Are Plenty of Coronary, Structural, and HF Trials Shelley Wood November 11, 2019
News Daily News DAPT Cuts Saphenous Vein Graft Failure After CABG: Meta-analysis Michael O'Riordan October 17, 2019
News Daily News Rivaroxaban Falls Flat in Antiphospholipid Antibody Syndrome Todd Neale October 15, 2019